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Abstract
Background: Infection by hepatitis B virus (HBV) causes complicated biochemical, immunological
and histological changes in host immune response against the virus which can be specific or non-
specific. Recent attention has focused on neopterin as a marker for the activation of cell mediated
immunity. The aim of this study was to define the pattern of neopterin levels in replicative and
nonreplicative HBV carriers.
Methods: Thirty HBV replicative carriers and 25 nonreplicative HBV carriers and 30 healthy adult
patients were included this study. Hepatitis markers were determined by commercial kit based on
chemilumminesans assay. HBV DNA was quantified by hybrid capture system. Serum neopterin
levels were measured by the method of competitive enzyme-linked immunosorbent assay. Results
were expressed as mean ± SD and ranges.
Results: In the nonreplicative group, except for one patient, all the patients' HBeAg were negative
and anti-HBe were positive. That particular patient was HBeAg positive and anti-HBe negative. In
the replicative group, 23 out of 30 patients have positive HBeAg and negative anti-HBe; 7 out of 30
patients have negative HBeAg and positive anti-HBe. Serum neopterin concentrations were 14.5 ±
10.0 (4.2–41) nmol/L in replicative HBV carriers, 8.9 ± 4.3 (2.1–22) nmol/L in nonreplicative HBV
carriers and 7.1 ± 2.2 (4.0–12) nmol/L in the control group. Serum neopterin levels and the rates
of abnormal serum neopterin levels in the replicative group were higher than the control group (P
< 0.01 and P < 0.05). In the nonreplicative group, serum neopterin levels were not different from
those of control. There was a difference between replicative and nonreplicative groups in the
respect of neopterin levels.
Conclusion: In the hepatitis B infected carriers, elevated neopterin levels may be an indicator of
the presence of replication.
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Background
Hepatitis B virus (HBV) infection is a worldwide health
problem. The clinical consequences of hepatitis B virus
infection are extremely variable, including clinical syn-
dromes such as fulminant, acute and chronic hepatitis,
hepatocellular carcinoma, and the asymptomatic carrier
state [1]. Infection by hepatitis B virus causes complicated
biochemical, immunological and histological changes in
host immune response against virus can be specific or
nonspecific. Nonspecific response occurs via cytokines or
other substance.
Neopterin is a pyrazino-pyrimidine derivative, namely 2-
amino 4-hydroxy-(1',2',3' trihydroxypropyl) pteridine.
Biosynthetically neopterin derives from guanosine tri-
phosphate [2]. Neopterin is produced by activated macro-
phages, in response to interferon-gamma derived from
activated T cell. Recent attention has focused on neopterin
as a marker for the activation of cell mediated immunity
[3]. Elevated neopterin levels in serum and urine have
been reported in several acute and chronic infections,
allograft rejection, autoimmune and malignant diseases
[2,4-7].
In some viral infections neopterin concentration increases
during the incubation period, shows a pronounced peak
during clinical symptoms and sharply decreases and nor-
malizes during the period of convalences, when neutraliz-
ing antibody titers become measurable in the circulation
[2].
The aim of this study is to define the pattern of neopterin
levels in replicative and nonreplicative HBV carriers.
Methods
Patients
This study included 55 patients infected with HBV for
more than 6 months and 30 healthy adult subjects as a
control group. All patients gave verbally informed consent
to participate in the study. A total of 30 HBV DNA (+)
patients were between the age of 13 and 73 years in the
replicative group, 25 HBV DNA (-) patients between 20
and 71 were included in the nonreplicative group. The
average age of 13 female and 17 male individuals in the
replicative group were 40.8 ± 15.3 (13–73). In the non-
replicative group, the average age of 10 female and 15
male individuals was 42.8 ± 13.4 (20–71). There are 30
health subjects in the control group consisted of 12
females and 18 male subjects. The average age of controls
was 44.1 ± 13.6 (21–68) years. The groups showed no sig-
nificant differences in age and sex. The diagnostic criterias
for HBV infection were sero-positivity for hepatitis B sur-
face antigen (HBsAg), lack of anti-hepatitis B surface anti-
bodies (anti HBs) and presence of anticore IgG antibodies
(anti-HBc). If serum HBV DNA levels was higher than 5
pg/ml by hybrid capture system, the patients were consid-
ered as HBV replicative carriers [8,9]. Of the 55 patients,
30 were HBV replicative carriers, 25 were nonreplicative
carriers when serum HBV-DNA undetectable by hybrid
capture system.
The control group included 30 healthy individuals with-
out HBV infection (HBsAg negative, antiHBs negative and
anti HBc IgG negative). All patient and controls were with-
out hepatitis C, hepatitis D, Human immunodeficiency
virus (HIV) infections and systemic bacterial or fungal
infection and autoimmune diseases. Other causes of liver
disease such as alcohol consumption and autoimmune
hepatitis were excluded.
Procedures
Viral markers (Access Beckman Coulter-Biorad, USA) and
biochemical parameters Synchron LX20, Beckman Coul-
ter, Brea, CA, USA) were determined by commercial kits.
HBV DNA was quantified by hybrid capture system
(Digene Diagnostic MD, USA), according to the manufac-
turer's instruction.
Serum neopterin levels
Serum neopterin levels were measured following the basic
principle of competitive enzyme-linked immunosorbent
assay (Neopterin ELISA, Immuno Biological Laboratories,
Hamburg, Germany): the competition between a peroxi-
dase-conjugated and nonconjugated antigen for a fixed
number of antibody binding sites (rabbit anti-neopterin).
The peroxidase-conjugated antigen-antibody complexes
bind to the wells of the microtiter strips, which are coated
with a goat anti-rabbit antibody. Unbound antigen was
removed by washing. After the substrate reaction the opti-
cal density was measured at 450 nm. Quantification of the
samples were estimated by comparing the enzymatic
activity of the samples with a response curve prepared by
using standards ranging 0 to 111 nmol/L. Results were
expressed as mean ± SD and ranges. Serum specimens
were stored at -20°C in the dark until the assay time.
Statistical analysis
For statistical analysis, Kruskal Wallis and Bonferroni
post-hoc tests were used. A p value of <0.05 was consid-
ered significant.
Results
The means of serum neopterin concentrations were 14.5 ±
10.0 (median: 11.5 ranged 4.2–41) nmol/L in replicative
HBV carriers, 8.9 ± 4.3 (median: 8.0 ranged 2.1–22)
nmol/L in nonreplicative HBV carriers and 7.1 ± 2.2
(median: 7.5 ranged 4.0–12) nmol/L in the control group.
The difference between the replicative, nonreplicative and
control was statistically significant ( P < 0.05). In the rep-
licative carriers neopterin levels (Table 1) and rates (TableBMC Infectious Diseases 2006, 6:157 http://www.biomedcentral.com/1471-2334/6/157
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2) were significantly higher than those of control (P < 0.01
and P < 0.05). Also, serum neopterin levels in replicative
group were higher than in nonreplicative groups (P <
0.05). There are no difference between men and women.
The levels of serum neopterin in 30 control and 30 repli-
cative and 25 nonreplicative patients were shown in Table
1 and 2 and Figure 1. In this study, when the cut-off value
was set as 8.7 nmol/L, 21 out of 30 replicative patients, 11
out of 25 nonreplicative patients and 11 out of 30 con-
trols' neopterin values were higher than this level (p <
0,05). On the other hand, when the cut-off value was set
as 10 nmol/L, 18 out of 30 replicative, 8 out of 25 nonrep-
licative and 5 out of 30 control subjects' neopterin values
were found to be higher than this point (p < 0,05) (Table
2).
Neopterin levels in nonreplicative carriers did not differ
from those of control. When HBV-DNA levels were cate-
gorized according to copy values as picogram, neopterin
levels were not correlated HBV-DNA levels (Table 4).
In the nonreplicative group, except for one patient, all the
patients' HBeAg were negative and anti-HBe were positive.
That particular patient's HBeAg was positive and anti-HBe
negative. In the replicative group, 23 out of 30 patients
have positive HBeAg and negative anti-HBe; 7 out of 30
patients have negative HBeAg and positive anti-HBe.
The averages of ALT levels were in reference limits accord-
ing to our laboratory for all groups. The mean of serum
ALT levels were 44 ± 14, 29 ± 11 and 26 ± 7.5 IU/L in the
replicative, nonreplicative carriers and control group,
respectively. Serum ALT levels were not different accord-
ing to interquartile range of serum neopterin (Table 3).
Discussions and conclusion
Immune defense against virus infection involves both
nonspecific and antigen-specific phases [1]. The stimula-
tion of the cellular immunity associated with macrophage
activation causes an increase of neopterin in the urine,
serum and other body fluids. Neopterin has been reported
as the indicator of local macrophage activity in different
body fluid. Neopterin secretion is found to increase in
patients suffering from viral, bacterial or parasitic infec-
tions and with immune and autoimmune diseases
[2,3,10]. Neopterin is considered as a parameter of
immun activation and inflammation [11]. Elevation of
neopterin levels in AIDS and tumor patients correlates
with the severity of the disease [12-14].
The measurement of HBV DNA levels in serum has
become an important tool for the identification of indi-
viduals with high levels of viral replication that might
benefit from antiviral therapy, monitoring of patients on
therapy, and prediction of whether antiviral therapy will
be successful. Several molecular approaches, commer-
cially available tests, have been used to quantity serum
HBV DNA levels [15]. Hybrid capture method was used in
this study to assess the viral load of the patient group. In
this study, if patients have >5 pg/ml viral load they are
called replicative; if the patients have not HBV DNA they
are called nonreplicative. In the present study serum
neopterin levels were examined in replicative HBV carriers
and nonreplicative HBV carriers. In the replicative HBV
carriers, the neopterin levels were found to be elevated.
Serum neopterin levels in the replicative group were sig-
nificantly higher than those of control group (P < 0.01).
Neopterin concentrations in serum show a slight increase
with age but not sex dependent difference [2,10,16]. As
the upper limit of serum neopterin in healthy controls
which are age between 19–75 years, 8.7 nmol/L are
accepted in some studies[2,10]. The cut-off value of our
kit is 10 nmol/L. We estimated of 83,3th percentile of
neopterin values of controls as <10 nmol/L. In present
study, 63,3th percentile of neopterin values of controls
were estimated as <8.7 nmol/L Therefore we decided that
our cut-off value as 10 nmol/L.
It is reported that clinically healthy HBsAg carriers have
normal neopterin levels [2]. Daito et al [17] have reported
that neopterin levels and rates of abnormal serum and uri-
nary values in asymptomatic HBsAg carriers did not differ
from those of controls, but in the acute hepatitis, neop-
terin levels were significantly higher than those normal
subjects. Serum neopterin levels in patients with B viral
chronic liver disease were significantly higher than those
in asymptomatic HBsAg. Kiliç et al [18] have reported that
Table 1: Serum neopterin levels in replicative, non replicative carriers and control
Groups Neopterin Levels (nmol/L)
Mean Median Standard Deviation Minimum Maximum
Replicative (n = 30) 14.5a, b 11.5 10.0 4.2 41
Non-replicative (n = 25) 8.8 8.0 4.3 2.1 22
Controls (n = 30) 7.1 7.5 2.2 4.0 12
a:P < 0.01 vs controls, b: P < 0.05 vs nonreplicativeBMC Infectious Diseases 2006, 6:157 http://www.biomedcentral.com/1471-2334/6/157
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neopterin levels were significantly increased in HBV carri-
ers without viral replication as compared with that of con-
trols. In another study, the levels of serum neopterin in
patients with hepatic cirrhosis have been found signifi-
cantly higher than the control groups. In cirrhotic patients
neopterin concentrations were not affected by the etiology
of liver disease [19]. In HCV positive patients, serum
neopterin levels were measured in several studies [20-22].
Grüngreiff et al [21] have found that elevated concentra-
tions of the neopterin in patients with chronic hepatitis C
infection before therapy (10.79 ± 5.51 nmol/L) compared
to healthy controls (1.25 ± 0.26 nmol/L) but, the differ-
ence was found negligible between responders and non-
responders during in the IFN therapy. The end of therapy
mean concentration was the lowest in partial responders,
and highest in non-responders. Neopterin levels in
healthy control in their study were lower than our study.
We can speculate that these differences may be due to
using different kits. Leonardi et al [22] found that serum
neopterin was higher in HCVAb positive than in HCVAb
negative patients. In another study, neopterin increased
from 1 to 2 weeks after the start of IFN-γ in HCV-RNA pos-
itive patients [20].
In this study, there was no correlation between neopterin
concentrations and HBV DNA levels in the replicative
group. It can be concluded that the neopterin level could
be related to the presence of the replication and not to the
quantity of the viral load. As the neopterin is produced as
a result of macrophage activation, neopterin level found
in this study to be higher in replicative group as compared
to nonreplicative and the control groups indicates that
cellular immune response continues in replicative group.
However, in this study, absence of increase in neopterin
serum levels in all replicative individuals, and the absence
of relation between the increase in neopterin levels and
the viral load, can derive from different immune response
of the host. Even though several other factors may cause
neopterin increase, in this study the rise of neopterin lev-
els until to 70% of the replicative group seem very signif-
icant.
In conclusion, in the Hepatitis B infected carriers, elevated
neopterin levels may be an indicator of the presence of
replication. Further studies may need to be carried out to
establish the relation between the increase in serum neop-
terin levels and virus replication in Hepatitis B carriers.
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Serum neopterin levels in patients with replicative, nonrepli- cative and control Figure 1
Serum neopterin levels in patients with replicative, nonrepli-
cative and control.
Table 2: Rates of Abnormal Serum Neopterin Levels in Various Groups
Groups Abnormal Serum Levels
No of cases ≥ 8,7 nmol/L ≥ 10 nmol/L
n%n %
Replicative 30 21a 70 18a 60
Non-replicative 25 11 44 8 32
Controls 30 11 36,6 5 16,6
a: P < 0.05 vs controlsBMC Infectious Diseases 2006, 6:157 http://www.biomedcentral.com/1471-2334/6/157
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Table 3: Serum ALT levels according to interquartil range of serum neopterin
Neoptein Quartile n Mean Std. Deviation Median Minimum Maximum
1 21 35.85 14.31 29 13 61
2 22 30.04 11.79 28.5 14 62
3 25 31.52 13.77 25.0 18 63
4 17 38.17 14.54 35.0 14 65
p > 0.05
Table 4: Serum neopterin levels according to HBV DNA in replicative group
HBVDNA (pg) Mean n Std. Deviation Median Minimum Maximum
5–100 17.7 8 10.2 14.0 9.5 41.0
101–500 12.7 7 9.1 10.5 4.0 31.0
501–1000 17.8 2 18.7 17.8 4.6 31.0
1000< 12.3 13 10.1 8.0 4.2 37.0